|
US20060222647A1
(en)
*
|
1993-05-27 |
2006-10-05 |
Beavo Joseph A |
Methods and compositions for modulating the activity of PDE5
|
|
GB9311920D0
(en)
|
1993-06-09 |
1993-07-28 |
Pfizer Ltd |
Therapeutic agents
|
|
US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
GB9423910D0
(en)
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9423911D0
(en)
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
GB9514464D0
(en)
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
|
ES2175404T3
(es)
|
1996-05-10 |
2002-11-16 |
Icos Corp |
Derivados de carbolina.
|
|
GB9612514D0
(en)
*
|
1996-06-14 |
1996-08-14 |
Pfizer Ltd |
Novel process
|
|
DE19642284A1
(de)
*
|
1996-10-14 |
1998-04-16 |
Merck Patent Gmbh |
Pyrazolinone zur Behandlung von Potenzstörungen
|
|
EP0977756A1
(en)
*
|
1997-04-25 |
2000-02-09 |
Pfizer Limited |
PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
|
|
AU739417B2
(en)
*
|
1997-05-29 |
2001-10-11 |
Mochida Pharmaceutical Co., Ltd. |
Therapeutic agent for erection dysfunction
|
|
US6399618B1
(en)
|
1997-07-09 |
2002-06-04 |
Cardiome Pharma Corp |
Compositions and methods for modulating sexual activity
|
|
US6103765A
(en)
|
1997-07-09 |
2000-08-15 |
Androsolutions, Inc. |
Methods for treating male erectile dysfunction
|
|
AU742787B2
(en)
|
1997-07-09 |
2002-01-10 |
Androsolutions, Inc. |
Improved methods and compositions for treating male erectile dysfunction
|
|
US20020025969A1
(en)
*
|
1997-07-09 |
2002-02-28 |
Wolf-Georg Forssmann |
Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
|
|
US20030077229A1
(en)
*
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
|
|
US6593369B2
(en)
|
1997-10-20 |
2003-07-15 |
Vivus, Inc. |
Methods, compositions, and kits for enhancing female sexual desire and responsiveness
|
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
|
US6548490B1
(en)
|
1997-10-28 |
2003-04-15 |
Vivus, Inc. |
Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
US6127363A
(en)
*
|
1997-10-28 |
2000-10-03 |
Vivus, Inc. |
Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
EP1027057A4
(en)
|
1997-10-28 |
2003-01-02 |
Vivus Inc |
TREATMENT OF FEMALE SEXUAL DISORDERS
|
|
US6156753A
(en)
*
|
1997-10-28 |
2000-12-05 |
Vivus, Inc. |
Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
EP1027054A4
(en)
*
|
1997-10-28 |
2002-11-04 |
Vivus Inc |
LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
|
|
US6403597B1
(en)
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
|
US6037346A
(en)
*
|
1997-10-28 |
2000-03-14 |
Vivus, Inc. |
Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
US6362178B1
(en)
*
|
1997-11-12 |
2002-03-26 |
Bayer Aktiengesellschaft |
2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
|
|
DE19752952A1
(de)
*
|
1997-11-28 |
1999-06-02 |
Merck Patent Gmbh |
Thienopyrimidine
|
|
ES2258300T3
(es)
*
|
1997-12-16 |
2006-08-16 |
Pfizer Products Inc. |
Combinacion de antagonistas del receptor alfa-1-adrenergico y un inhibidor gmpc pdev para el tratamiento de la impotencia.
|
|
TW542719B
(en)
*
|
1998-02-23 |
2003-07-21 |
Pfizer Res & Dev |
Method of treating impotence due to spinal cord injury
|
|
HRP20000712A2
(en)
|
1998-04-20 |
2001-06-30 |
Pfizer |
PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
|
|
DE19819023A1
(de)
*
|
1998-04-29 |
1999-11-04 |
Merck Patent Gmbh |
Thienopyrimidine
|
|
US6110489A
(en)
*
|
1998-05-01 |
2000-08-29 |
Cutler; Neal R. |
Use of quinolines and quinolones to treat male erectile dysfunction
|
|
US6426084B1
(en)
|
2000-06-19 |
2002-07-30 |
Neal R. Cutler |
Treatment of sexual dysfunction in certain patient groups
|
|
MXPA00010254A
(es)
*
|
1998-05-01 |
2002-08-06 |
R Cutler Neal |
Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
|
|
US6132753A
(en)
*
|
1998-05-01 |
2000-10-17 |
Neal R. Cutler |
Treatment of sexual dysfunction in certain patient groups
|
|
US6187790B1
(en)
|
1999-03-04 |
2001-02-13 |
Neal R. Cutler |
Use of cilostazol for treatment of sexual dysfunction
|
|
US6194433B1
(en)
|
1998-10-05 |
2001-02-27 |
Neal R. Cutler |
Sexual dysfunction in females
|
|
US6541487B1
(en)
|
1998-05-01 |
2003-04-01 |
R.T. Alamo Ventures I, Llc |
PDE III inhibitors for treating sexual dysfunction
|
|
US6132757A
(en)
*
|
1998-05-01 |
2000-10-17 |
Neal R. Cutler |
Treatment of sexual dysfunction in certain patient groups
|
|
AU4068599A
(en)
*
|
1998-05-20 |
1999-12-06 |
Schering Corporation |
Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
|
|
EP0967284A1
(en)
*
|
1998-05-28 |
1999-12-29 |
Pfizer Limited |
Phosphodiesterases
|
|
TWI223598B
(en)
*
|
1998-06-22 |
2004-11-11 |
Pfizer Ireland Pharmaceuticals |
An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
|
|
JP2002518417A
(ja)
|
1998-06-25 |
2002-06-25 |
ラヴィファム ラボラトリーズ インコーポレーテッド |
勃起機能不全の治療装具及び方法
|
|
US7087240B1
(en)
|
1998-06-25 |
2006-08-08 |
Lavipharm Laboratories Inc. |
Device and method for the treatment of erectile dysfunction
|
|
WO2000000199A1
(en)
*
|
1998-06-26 |
2000-01-06 |
Nastech Pharmaceutical Company, Inc. |
Nasal delivery of sildenafil citrate
|
|
DE19837067A1
(de)
|
1998-08-17 |
2000-02-24 |
Bayer Ag |
Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
|
|
US6476078B2
(en)
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
|
ATE264861T1
(de)
*
|
1998-09-04 |
2004-05-15 |
Ortho Mcneil Pharm Inc |
5-heterozyklyl-pyrazolo(4,3-d)pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen
|
|
CA2346350C
(en)
|
1998-10-05 |
2008-01-08 |
Eisai Co., Ltd. |
Intraoral quickly disintegrating tablets
|
|
JP2000178204A
(ja)
*
|
1998-10-05 |
2000-06-27 |
Eisai Co Ltd |
ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
|
|
JP2000191518A
(ja)
*
|
1998-10-19 |
2000-07-11 |
Eisai Co Ltd |
溶解性の改善された口腔内速崩壊性錠剤
|
|
GB9823103D0
(en)
*
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
UA67802C2
(uk)
|
1998-10-23 |
2004-07-15 |
Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. |
Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
|
|
GB9823102D0
(en)
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
GB9823101D0
(en)
*
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
RU2220145C2
(ru)
*
|
1998-11-11 |
2003-12-27 |
Донг А Фарм. Ко., Лтд. |
Производные пиразолопиримидинона для лечения импотенции и способ их получения
|
|
KR100353014B1
(ko)
*
|
1998-11-11 |
2002-09-18 |
동아제약 주식회사 |
발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
|
|
US6225315B1
(en)
|
1998-11-30 |
2001-05-01 |
Pfizer Inc |
Method of treating nitrate-induced tolerance
|
|
GB9828340D0
(en)
*
|
1998-12-22 |
1999-02-17 |
Novartis Ag |
Organic compounds
|
|
US6455564B1
(en)
|
1999-01-06 |
2002-09-24 |
Pharmacia & Upjohn Company |
Method of treating sexual disturbances
|
|
AU3210500A
(en)
*
|
1999-01-22 |
2000-08-07 |
Selectus Pharmaceuticals, Inc. |
Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence
|
|
WO2000053148A2
(en)
*
|
1999-03-08 |
2000-09-14 |
Merck & Co., Inc. |
Methods and compositions for treating erectile dysfunction
|
|
CA2368023A1
(en)
|
1999-03-22 |
2000-09-28 |
Guixue Yu |
Fused pyridopyridazine inhibitors of cgmp phosphodiesterase
|
|
US6214849B1
(en)
|
1999-04-29 |
2001-04-10 |
Lupin Laboratories Limited |
Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans
|
|
US6451807B1
(en)
*
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
|
ES2187234A1
(es)
*
|
1999-04-30 |
2003-05-16 |
Lilly Icos Llc |
Forma de dosificacion oral para tratar la disfuncion sexual.
|
|
US7258850B2
(en)
*
|
1999-05-04 |
2007-08-21 |
Aradigm Corporation |
Methods and compositions for treating erectile dysfunction
|
|
US6242444B1
(en)
|
1999-06-04 |
2001-06-05 |
The Jordanian Pharmaceutical Manufacturing And Medical Equipment Co., Ltd. |
Compounds and pharmaceutical compositions containing the same
|
|
AU5204800A
(en)
*
|
1999-06-21 |
2001-01-09 |
Biochemical Pharmaceutical Factory of Zhuhai Sez, The |
Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine
|
|
US6303135B1
(en)
|
1999-07-08 |
2001-10-16 |
Neal R. Cutler |
Use of quinolines and quinolones to treat male erectile dysfunction
|
|
CN1077108C
(zh)
*
|
1999-07-13 |
2002-01-02 |
成都地奥制药集团有限公司 |
用于制备药物昔多芬的前体化合物
|
|
IL130968A
(en)
|
1999-07-15 |
2002-12-01 |
Shmuel Simon |
Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
|
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
|
DE19944161A1
(de)
*
|
1999-09-15 |
2001-03-22 |
Bayer Ag |
Neue Kombination zur Behandlung von sexueller Dysfunktion
|
|
EP1219609B1
(en)
|
1999-09-16 |
2007-04-04 |
Tanabe Seiyaku Co., Ltd. |
Aromatic nitrogenous six-membered ring compounds
|
|
US6436944B1
(en)
|
1999-09-30 |
2002-08-20 |
Pfizer Inc. |
Combination effective for the treatment of impotence
|
|
AP2002002455A0
(en)
*
|
1999-10-11 |
2002-06-30 |
Pfizer |
5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
|
|
TWI265925B
(en)
|
1999-10-11 |
2006-11-11 |
Pfizer |
Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
|
|
US20050070499A1
(en)
*
|
1999-11-08 |
2005-03-31 |
Pfizer Inc. |
Compounds for the treatment of female sexual dysfunction
|
|
IL150022A0
(en)
|
1999-12-24 |
2002-12-01 |
Bayer Ag |
Imidazo [1,3,5] triazinones and the use thereof
|
|
KR100358083B1
(ko)
*
|
2000-02-17 |
2002-10-25 |
에스케이케미칼주식회사 |
피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
|
|
DE10010067A1
(de)
*
|
2000-03-02 |
2001-09-06 |
Bayer Ag |
Neue Imidazotriazinone und ihre Verwendung
|
|
US7019136B2
(en)
|
2000-04-07 |
2006-03-28 |
Novartis, Ag |
8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
|
|
GB0008694D0
(en)
*
|
2000-04-07 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
|
DE10017947A1
(de)
*
|
2000-04-11 |
2001-10-25 |
Merck Patent Gmbh |
Verfahren zur Herstellung benzo-annelierter Heterocyclen
|
|
NZ522217A
(en)
|
2000-04-28 |
2004-04-30 |
Tanabe Seiyaku Co |
Cyclic compounds
|
|
US7273868B2
(en)
|
2000-04-28 |
2007-09-25 |
Tanabe Seiyaku Co., Ltd. |
Pyrazine derivatives
|
|
UA74826C2
(en)
*
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
|
AU2000254308A1
(en)
*
|
2000-05-17 |
2001-11-26 |
Sk Chemicals Co., Ltd. |
Pyrazolopyrimidinone derivatives, process for their preparation and their use
|
|
US6730786B2
(en)
|
2000-06-22 |
2004-05-04 |
Pfizer Inc |
Process for the preparation of pyrazolopyrimidinones
|
|
US6667398B2
(en)
|
2000-06-22 |
2003-12-23 |
Pfizer Inc |
Process for the preparation of pyrazolopyrimidinones
|
|
DE10031584A1
(de)
|
2000-06-29 |
2002-01-10 |
Merck Patent Gmbh |
5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
|
|
DE10031585A1
(de)
|
2000-06-29 |
2002-01-10 |
Merck Patent Gmbh |
2-Aminoalkyl-thieno[2,3-d]pyrimidine
|
|
AU2001276403A1
(en)
*
|
2000-07-12 |
2002-01-21 |
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts |
Use of inhibitors to multidrug resistance protein 5 (mrp5) to enhance intracellular levels of cyclic nucleotides
|
|
BRPI0003386B8
(pt)
*
|
2000-08-08 |
2021-05-25 |
Cristalia Produtos Quim Farmaceuticos Ltda |
pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
|
|
PE20020394A1
(es)
|
2000-08-18 |
2002-06-21 |
Agouron Pharma |
Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
|
|
WO2002016364A1
(en)
*
|
2000-08-23 |
2002-02-28 |
Lg Life Sciences Ltd. |
Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
|
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
|
NZ524572A
(en)
|
2000-09-06 |
2004-08-27 |
Tanabe Seiyaku Co |
Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
|
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
GB0025782D0
(en)
*
|
2000-10-20 |
2000-12-06 |
Pfizer Ltd |
Use of inhibitors
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
EP1201243B1
(en)
*
|
2000-10-23 |
2003-09-03 |
The Jordanian Pharmaceutical Manufacturing and Medical Equipment Co.Ltd. |
Use of sulfadiazine and sulfadimidine for treating erectile dysfunction
|
|
DE10063108A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Bayer Ag |
Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
|
|
SE0004780D0
(sv)
|
2000-12-22 |
2000-12-22 |
Jordanian Pharmaceutical Mfg & |
Novel compunds
|
|
JP3940290B2
(ja)
*
|
2000-12-22 |
2007-07-04 |
ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド |
新規化合物
|
|
JP2004525890A
(ja)
*
|
2001-02-02 |
2004-08-26 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
|
|
NZ527585A
(en)
|
2001-02-15 |
2005-04-29 |
Tanabe Seiyaku Co |
Tablets quickly disintegrated in oral cavity
|
|
DE10107639A1
(de)
*
|
2001-02-15 |
2002-08-22 |
Bayer Ag |
2-Alkoxyphenyl-substituierte Imidazotriazinone
|
|
MXPA03007623A
(es)
|
2001-02-26 |
2003-12-04 |
Tanabe Seiyaku Co |
Derivado de piridopirimidina o naftiridina.
|
|
EP1372656B1
(en)
*
|
2001-03-16 |
2005-06-22 |
Pfizer Limited |
Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors
|
|
US6784185B2
(en)
|
2001-03-16 |
2004-08-31 |
Pfizer Inc. |
Pharmaceutically active compounds
|
|
US20030054531A1
(en)
*
|
2001-03-19 |
2003-03-20 |
Decode Genetics Ehf, |
Human stroke gene
|
|
US20040014099A1
(en)
*
|
2001-03-19 |
2004-01-22 |
Decode Genetics Ehf. |
Susceptibility gene for human stroke; methods of treatment
|
|
WO2004028341A2
(en)
*
|
2001-03-19 |
2004-04-08 |
Decode Genetics Ehf. |
Susceptibility gene for human stroke; methods of treatment
|
|
US20050164220A1
(en)
*
|
2001-03-19 |
2005-07-28 |
Decode Genetics Ehf. |
Susceptibility gene for human stroke: method of treatment
|
|
US6794387B2
(en)
|
2001-03-28 |
2004-09-21 |
Pfizer Inc. |
Pharmaceutically active compounds
|
|
GB0107751D0
(en)
*
|
2001-03-28 |
2001-05-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
DE10118306A1
(de)
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
|
|
US6610887B2
(en)
|
2001-04-13 |
2003-08-26 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
|
EP1404336A1
(en)
*
|
2001-06-14 |
2004-04-07 |
Sampad Bhattacharya |
Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
|
|
KR100393160B1
(ko)
*
|
2001-06-14 |
2003-07-31 |
한국과학기술연구원 |
신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
|
|
CN1127506C
(zh)
*
|
2001-06-29 |
2003-11-12 |
刘宝顺 |
一种治疗阳痿的新化合物
|
|
DE10135815A1
(de)
|
2001-07-23 |
2003-02-06 |
Bayer Ag |
Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
|
|
WO2003020724A1
(en)
|
2001-08-28 |
2003-03-13 |
Schering Corporation |
Polycyclic guanine phosphodiesterase v inhibitors
|
|
EP1790652A1
(en)
*
|
2001-08-28 |
2007-05-30 |
Schering Corporation |
Polycyclic guanine phosphodiesterase V inhibitors
|
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
|
CA2465893A1
(en)
*
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase v inhibitors
|
|
DE60222931T2
(de)
*
|
2001-12-13 |
2008-07-10 |
Asubio Pharma Co., Ltd. |
Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
|
|
US7645878B2
(en)
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
|
MXPA04011865A
(es)
*
|
2002-05-31 |
2005-03-31 |
Schering Corp |
Polimorfos inhibidores de xantina fosfodiesterasa v.
|
|
EP1719772A1
(en)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
|
|
US6800625B2
(en)
|
2002-06-19 |
2004-10-05 |
Janssen Pharmaceutica N.V. |
Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors
|
|
DE10232113A1
(de)
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
|
|
WO2004072079A1
(en)
*
|
2003-02-11 |
2004-08-26 |
Pfizer Limited |
Hydrated and anhydrous sildenafil hemi-citrate compound
|
|
DE10325813B4
(de)
|
2003-06-06 |
2007-12-20 |
Universitätsklinikum Freiburg |
Prophylaxe und/oder Therapie bei der portalen Hypertonie
|
|
CN100374441C
(zh)
|
2003-06-06 |
2008-03-12 |
天津倍方科技发展有限公司 |
二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
|
|
PL1644021T3
(pl)
*
|
2003-06-13 |
2013-01-31 |
Ironwood Pharmaceuticals Inc |
Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
|
|
WO2005034987A1
(en)
*
|
2003-10-13 |
2005-04-21 |
Studio Legale Avv Aldo Ferrini E Avv. Manuele Bianchi |
Use of lh for generating libido and reaching orgasm in female subjects
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
EP1695735A1
(en)
*
|
2003-12-02 |
2006-08-30 |
Hakuju Institute for Health Science Co., Ltd |
Nonpharmacological generative function control method and its apparatus
|
|
CN100360531C
(zh)
*
|
2003-12-18 |
2008-01-09 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
|
|
US9226909B2
(en)
|
2004-04-19 |
2016-01-05 |
Strategic Science & Technologies, Llc |
Beneficial effects of increasing local blood flow
|
|
WO2005102307A2
(en)
*
|
2004-04-19 |
2005-11-03 |
Strategic Science & Technologies, Llc |
Beneficial effects of increasing local blood flow
|
|
SI1750766T1
(sl)
|
2004-05-11 |
2013-11-29 |
Emotional Brain B.V. |
Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah
|
|
US7700608B2
(en)
|
2004-08-04 |
2010-04-20 |
Shire Holdings Ag |
Quinazoline derivatives and their use in the treatment of thrombocythemia
|
|
US20060030574A1
(en)
|
2004-08-04 |
2006-02-09 |
Shire Holdings Ag |
Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
|
|
CN101014321A
(zh)
*
|
2004-08-23 |
2007-08-08 |
曼金德公司 |
5型磷酸二酯酶抑制剂的肺部给予
|
|
CN100347174C
(zh)
*
|
2004-09-10 |
2007-11-07 |
上海特化医药科技有限公司 |
杂环并嘧啶酮衍生物、制备方法和用途
|
|
AU2005296719B2
(en)
|
2004-10-18 |
2011-02-03 |
Polymun Scientific Immunbiologische Forschung Gmbh |
Liposomal composition comprising an active ingredient for relaxing smooth muscle production and therapeutically use of said composition
|
|
DE102005009240A1
(de)
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
|
|
US20060235005A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Oak Labs, Corp. |
Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
|
|
UA84688C2
(uk)
*
|
2005-04-15 |
2008-11-25 |
Виктор Павлович Кутняк |
Засіб для лікування еректильної дисфункції
|
|
RU2336878C2
(ru)
*
|
2005-05-16 |
2008-10-27 |
Виктор Павлович Кутняк |
Средство для лечения эректильной дисфункции
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
EP1928437A2
(en)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
US20090186896A1
(en)
*
|
2005-09-29 |
2009-07-23 |
Bayer Healthcare Ag |
PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
|
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
WO2007056457A2
(en)
|
2005-11-09 |
2007-05-18 |
Combinatorx, Incorporated |
Methods, compositions, and kits for the treatment of medical conditions
|
|
EP1790343A1
(en)
|
2005-11-11 |
2007-05-30 |
Emotional Brain B.V. |
Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
|
|
CN1966506A
(zh)
|
2005-11-17 |
2007-05-23 |
上海特化医药科技有限公司 |
吡唑并嘧啶酮衍生物及其制备方法和用途
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20080027072A1
(en)
*
|
2006-04-20 |
2008-01-31 |
Ampla Pharmaceuticals, Inc. |
Potentiation of MC4 receptor activity
|
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
WO2007134077A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
CN101495122B
(zh)
*
|
2006-05-15 |
2011-10-05 |
联合治疗公司 |
使用定量吸入器给予曲前列尼
|
|
EP2068872A1
(en)
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
DE102006043443A1
(de)
|
2006-09-15 |
2008-03-27 |
Bayer Healthcare Ag |
Neue aza-bicyclische Verbindungen und ihre Verwendung
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP1925307A1
(en)
*
|
2006-11-03 |
2008-05-28 |
Emotional Brain B.V. |
Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
|
|
US7910597B2
(en)
|
2006-11-28 |
2011-03-22 |
Shire Llc |
Substituted quinazolines
|
|
US8071765B2
(en)
|
2006-12-21 |
2011-12-06 |
Topharman Shanghai Co., Ltd. |
Process for the preparation of sildenafil and intermediates thereof
|
|
CN101657101B
(zh)
*
|
2007-02-12 |
2013-12-11 |
Dmi生物科学公司 |
并存早泄和勃起功能障碍的治疗
|
|
US20080194529A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Auspex Pharmaceuticals, Inc. |
HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
|
|
CN101674728A
(zh)
*
|
2007-02-12 |
2010-03-17 |
Dmi生物科学公司 |
降低曲马多的副作用
|
|
ES2310144B1
(es)
|
2007-06-15 |
2010-01-12 |
Galenicum Health, S.L. |
Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
|
|
DE102007028869A1
(de)
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
|
US20090181975A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
|
HRP20151357T1
(hr)
|
2008-05-02 |
2016-01-29 |
Gilead Sciences, Inc. |
Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa
|
|
EP2305237B1
(en)
*
|
2008-05-14 |
2014-04-30 |
SBI Pharmaceuticals Co., Ltd. |
Therapeutic agent for male sterility
|
|
CN101747282A
(zh)
|
2008-12-10 |
2010-06-23 |
上海特化医药科技有限公司 |
一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
|
|
US20110244050A1
(en)
*
|
2008-12-12 |
2011-10-06 |
Siegfried Rhein S.A. De C.V. |
Pulsed-release sildenafil composition and method for preparing said composition
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
WO2010070617A1
(en)
|
2008-12-19 |
2010-06-24 |
Shimoda Biotech (Pty) Ltd |
Inclusion complexes of alpha-cyclodextrin and sildenafil salt
|
|
RU2391095C1
(ru)
*
|
2009-02-05 |
2010-06-10 |
Закрытое акционерное общество "Березовский фармацевтический завод" |
Фармацевтическая композиция, включающая холина альфосцерат и гопантеновую кислоту (или ее соль), для лечения недостаточности кровообращения мозга и эректильной дисфункции
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
US20100261737A1
(en)
*
|
2009-04-10 |
2010-10-14 |
Medtronic Vascular, Inc. |
Method of Treating Erectile Dysfunction
|
|
SG177281A1
(en)
|
2009-06-19 |
2012-02-28 |
Nanoform Hungary Ltd |
Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
|
|
US12138268B2
(en)
|
2009-06-24 |
2024-11-12 |
Strategic Science & Technologies, Llc |
Treatment of erectile dysfunction and other indications
|
|
US11684624B2
(en)
|
2009-06-24 |
2023-06-27 |
Strategic Science & Technologies, Llc |
Treatment of erectile dysfunction and other indications
|
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
|
DE102009035211A1
(de)
|
2009-07-29 |
2011-02-17 |
Ratiopharm Gmbh |
Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
|
|
EP2493434A1
(en)
|
2009-10-30 |
2012-09-05 |
Medispec Ltd |
Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves
|
|
PH12012501023A1
(en)
|
2009-11-27 |
2014-12-19 |
Adverio Pharma Gmbh |
Method for producing methyl - {4, 6-diamino -2-[1- (2-fluorobenzyl) -1h- pyrazolo [3,4-b] pyridino -3-yl] pyrimidino -5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance
|
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
|
JP5806231B2
(ja)
|
2009-12-21 |
2015-11-10 |
アセフ エス．アー． |
勃起障害の治療における血管拡張剤としてのクベビン、ジベンジルブチルロラクトリンリグナン、その半合成誘導体および合成誘導体、ならびに他のリグナンおよびネオリグナン
|
|
EA023221B1
(ru)
|
2010-02-27 |
2016-05-31 |
Байер Интеллектуэль Проперти Гмбх |
СВЯЗАННЫЕ БИС-АРИЛЬНЫЕ АРИЛ-ТРИАЗОЛОНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И ДВОЙНОЙ АНТАГОНИСТ V1a/V2-РЕЦЕПТОРОВ
|
|
EP3108888B1
(en)
|
2010-03-15 |
2020-02-12 |
United Therapeutics Corporation |
Treatment for pulmonary hypertension
|
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
|
WO2012000634A1
(de)
|
2010-06-29 |
2012-01-05 |
Georg Bambach |
Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
|
|
CN101891747B
(zh)
*
|
2010-07-02 |
2012-04-25 |
张南 |
抑制5型磷酸二酯酶的化合物及制备方法
|
|
TW201210584A
(en)
|
2010-08-18 |
2012-03-16 |
Alcon Res Ltd |
Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
|
|
DE102010040187A1
(de)
|
2010-09-02 |
2012-03-08 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
|
|
DE102010040924A1
(de)
|
2010-09-16 |
2012-03-22 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
|
|
EP4491225A3
(en)
|
2010-12-29 |
2025-03-26 |
Strategic Science & Technologies, LLC |
Treatment of erectile dysfunction and other indications
|
|
MX2013008791A
(es)
|
2011-02-02 |
2013-10-07 |
Irm Llc |
Metodos para usar inhibidores de alk.
|
|
US8623924B2
(en)
|
2011-07-15 |
2014-01-07 |
Nusirt Sciences, Inc. |
Compositions and methods for modulating metabolic pathways
|
|
AT512084A1
(de)
|
2011-10-20 |
2013-05-15 |
Univ Wien Tech |
Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
|
|
US9402877B2
(en)
|
2011-11-04 |
2016-08-02 |
Xion Pharmaceuticals Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
WO2013106547A1
(en)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
CN104168895B
(zh)
|
2012-02-28 |
2020-02-21 |
首尔制药株式会社 |
包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
|
|
US9198454B2
(en)
|
2012-03-08 |
2015-12-01 |
Nusirt Sciences, Inc. |
Compositions, methods, and kits for regulating energy metabolism
|
|
MX2015006023A
(es)
|
2012-11-13 |
2016-03-31 |
Nusirt Sciences Inc |
Composiciones y metodos para incrementar el metabolismo energetico.
|
|
US9750743B2
(en)
|
2012-12-04 |
2017-09-05 |
Aribio Inc. |
Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
|
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
|
CN105102457A
(zh)
|
2013-02-21 |
2015-11-25 |
阿德弗里奥药品有限责任公司 |
{4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
|
|
CN105228627B
(zh)
|
2013-03-15 |
2018-07-13 |
纽斯尔特科学公司 |
亮氨酸和烟酸降低脂质水平
|
|
EP3110507B1
(en)
|
2014-02-27 |
2020-11-18 |
NuSirt Sciences, Inc. |
Compositions and methods for the reduction or prevention of hepatic steatosis
|
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
|
UA121558C2
(uk)
|
2014-11-03 |
2020-06-25 |
Баєр Фарма Актіенгезеллшафт |
Гідроксіалкілзаміщені фенілтриазольні похідні та їх застосування
|
|
CN104650093B
(zh)
*
|
2015-02-02 |
2017-01-25 |
王靖林 |
一种西地那非类似物的合成方法
|
|
WO2017168174A1
(en)
|
2016-04-02 |
2017-10-05 |
N4 Pharma Uk Limited |
New pharmaceutical forms of sildenafil
|
|
US9988367B2
(en)
|
2016-05-03 |
2018-06-05 |
Bayer Pharma Aktiengesellschaft |
Amide-substituted pyridinyltriazole derivatives and uses thereof
|
|
US20190328869A1
(en)
|
2016-10-10 |
2019-10-31 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
US10568847B2
(en)
*
|
2016-12-13 |
2020-02-25 |
James J. Caprio |
Compositions and methods for treatment of erectile dysfunction
|
|
WO2018134848A1
(en)
|
2017-01-20 |
2018-07-26 |
Laila Nutraceuticals |
Dietary supplements for inhibiting pde5 and increasing cgmp levels
|
|
KR20240113607A
(ko)
|
2017-06-21 |
2024-07-22 |
트랜스진 |
개인 맞춤형 백신
|
|
KR102323090B1
(ko)
*
|
2017-07-07 |
2021-11-05 |
상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 |
페닐 피리미돈 화합물의 염, 다형체 및 이의 약학 조성물 및 용도
|
|
JP2021516957A
(ja)
|
2018-03-07 |
2021-07-15 |
トランジェーヌＴｒａｎｓｇｅｎｅ |
パラポックスウイルスベクター
|
|
WO2019241585A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
|
|
US20190385720A1
(en)
*
|
2018-06-14 |
2019-12-19 |
AstraZeneca UK Litimited |
Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
|
|
SE542968C2
(en)
|
2018-10-26 |
2020-09-22 |
Lindahl Anders |
Treatment of osteoarthritis
|
|
JP7625521B2
(ja)
|
2018-12-28 |
2025-02-03 |
トランスジーン |
ｍ２欠陥ポックスウイルス
|
|
CN113493459B
(zh)
*
|
2020-04-07 |
2022-12-13 |
广州白云山医药集团股份有限公司白云山制药总厂 |
Pde5抑制剂化合物及其制备方法和应用
|
|
CN111732593A
(zh)
*
|
2020-07-07 |
2020-10-02 |
黄泳华 |
哌嗪氧化物衍生物及其组合物、制备方法与用途
|
|
CN115785101B
(zh)
*
|
2022-11-23 |
2023-10-13 |
西安市食品药品检验所 |
一种含有苯基哌嗪结构的那非类化合物及其制备方法
|
|
KR20240117491A
(ko)
|
2023-01-25 |
2024-08-01 |
주식회사 아리바이오 |
포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물
|